Current non-invasive approaches for bladder cancer (BC) detection are 49 suboptimal. We report the development of non-invasive molecular test for BC using 50 DNA recovered from cells shed into urine. This "UroSEEK" test incorporates assays for 51 mutations in 11 genes and copy number changes on 39 chromosome arms. We first 52 evaluated 570 urine samples from patients at risk for BC (microscopic hematuria or 53 dysuria). UroSEEK was positive in 83% of patients that developed BC, but in only 7% of 54 patients who did not develop BC. Combined with cytology, 95% of patients that 55 developed BC were positive. We then evaluated 322 urine samples from patients soon 56 after their BCs had been surgically resected. UroSEEK detected abnormalities in 66% 57 of the urine samples from these patients, sometimes up to 4 years prior to clinical 58 evidence of residual neoplasia, while cytology was positive in only 25% of such urine 59 samples. The advantages of UroSEEK over cytology were particularly evident in low-60 grade tumors, wherein cytology detected none while UroSEEK detected 67% of 49 61 cases. These results establish the foundation for a new, non-invasive approach to the 62 detection of BC in patients at risk for initial or recurrent disease. 63 64 65 Bladder cancer (BC) is the most common malignancy of the urinary tract. According to 66 the American Cancer Society, 79,030 new cases of bladder cancer and 18,540 deaths 67 are estimated to occur in the United States alone in 2017 [1]. Predominantly of urothelial 68 histology, invasive BC arises from non-invasive papillary or flat precursors. Many BC 69 patients suffer with multiple relapses prior to progression, providing ample lead-time for 70 early detection and treatment prior to metastasis [2]. Urine cytology and cystoscopy with 71 transurethral biopsy (TURB) are currently the gold standards for diagnosis and follow-up 72 in bladder cancer. While urine cytology has value for the detection of high-grade 73 neoplasms, it is unable to detect the vast majority of low-grade tumors [3-5]. This fact, 74 together with the high cost and invasive nature of repeated cystoscopy and TURB 75 procedures, have led to many attempts to develop novel noninvasive strategies. These 76 include urine or serum based genetic and protein assays for screening and surveillance 77 [6-21]. Currently available U.S. Food and Drug Administration (FDA) approved assays 78 include ImmunoCyt test (Scimedx Corp), nuclear matrix protein 22 (NMP22) 79
Early Detection Cohort 177 178 Cohort characteristics. A total 570 patients were included in the Early Detection 179 cohort, each with one urine sample analyzed. 90% of the patients had hematuria, 3% 180 had lower urinary tract symptoms (LUTS), and 9% had other indications suggesting they 181 were at risk for BC. The median age of the participants was 58 years (range 5 to 89) 182 ( Supplementary Table 1 ). As expected from prior studies of patients at risk for BC, 70% 183 of the patients were male [1, 43] . 175 (31%) of patients developed BC after a median 184 follow-up period of 18 months (range 0 to 40 months). For each patient who developed 185 BC, we selected two other patients who presented with similar symptoms but did not 186 develop BC during the follow-up period. By design, then, the fraction of cases in this 187 cohort developing BC was higher than the fraction (5%) of patients with similar 191 192 Genetic analysis. We performed three separate tests for genetic abnormalities that 193 might be found in urinary cells derived from BC ( Figure 2 ). First, we evaluated 194 mutations in selected regions of ten genes that have been shown to be frequently 195 altered in urothelial tumors (Supplementary File 2) . For this purpose, we designed a 196 specific set of primers that allowed us to detect mutations in as few as 0.03% of urinary 197 cells. The capacity to detect such low mutant fractions was a result of the incorporation 198 of molecular barcodes in each of the primers, thereby substantially reducing the artifacts 199 associated with massively parallel sequencing [41] . Second, we evaluated TERT 200 promoter mutations. A singleplex PCR was used for this analysis because the unusually 201 high GC-content of the TERT promoter precluded its inclusion in the multiplex PCR 202 design. Third, we evaluated the extent of aneuploidy using a technique in which a 203 single PCR is used to co-amplify ~38,000 members of a subfamily of long interspersed 213  214  215  216  217  218  219  220  221  222  223  224  225  226  227   8 The multiplex assay detected mutations in 68% of the 175 urinary cell samples from the 228 individuals that developed BC during the course of this study (95% CI 61% to 75%)
229
( Supplementary Table 1 and Supplementary File 2). A total of 246 mutations were 230 detected in 8 of the ten target genes (Figure 2A and Supplementary File 2). The mean 231 mutant allele frequency in the urinary cells with detectable mutations was 18% and 232 ranged from 0.17% to 99%. The most commonly altered genes were TP53 (45% of the 233 total mutations) and FGFR3 (20% of the total mutations; Fig. 2A ). The distribution of 234 mutant genes was roughly consistent with expectations based on previous exome-wide 235 sequencing studies of BCs [46] . At the thresholds used, 1.7% of the 395 patients in the 236 Early Detection Cohort who did not develop BC during the course of the study had a 237 detectable mutation in any of the ten genes. At the same thresholds, none of the 188 238 urinary cell samples from healthy individuals had any mutation in any of the ten genes 239 assayed (100% specificity, 95% CI 98% to 100%).
241
Mutations in the TERT promoter were detected in 57% of the 175 urinary cell samples 242 from the patients that developed cancer during the study interval (95% CI 49% to 64%;
243 Supplementary Table 1 and Supplementary File 3). The mean TERT mutant allele 244 frequency in the urinary cells was 14% and ranged from 0.18% to 78%. Mutations were 245 detected in 3 positions: 98% of the mutations were at hg1295228 (79%) and hg Comparison with primary tumors. Tumor samples from 102 of the patients enrolled 267 in this cohort were available for comparison and were studied with the same three 268 assays used to study the urinary cell samples (Supplementary File 3). In 91 (89%) of 269 these 102 cancers, at least one mutation in the eleven genes studied were mutated (in on the basis for "false negatives", i.e., the reason that 21% of urine samples from 274 patients who developed BC had no detectable mutations in the 11 genes tested. The 275 reason could either have been that the corresponding BC did not harbor a mutation in 276 these 11 genes or that it did, but the fraction of neoplastic cells in the urine sample was 277 not high enough to allow its detection with the assays we used. We could identify a 278 mutation in at least one of the 11 genes in 62% of the primary tumors from patients with 279 false negative urine tests for mutations (Supplementary File 5 and 6). We conclude 280 that 38% of the 29 false negative tests for mutations were due to the fact that none of 281 the queried mutations were present in the tumor and that the other 62% of the false 282 negatives were due to insufficient amounts of cancer cells in the urine.
284
UroSEEK: biomarkers in combination. As noted above, the ten-gene multiplex assay, 285 the TERT singleplex assay, and the aneuploidy assays yielded 68%, 57%, and 46% 286 sensitivities, respectively, when used separately ( Supplementary Table 1 File 3). Ten of the urinary cell samples without any detectable mutations in the 11 292 genes could be detected by the assay for aneuploidy ( Figure 3A and Supplementary   293   Table 4 ). Thus, when the three assays were used together (test termed "UroSEEK"), 294 and a positive result in either assay was sufficient to score a sample as positive, the 295 sensitivity rose to 83% (95% CI 76% to 88 %). Only one of the 188 samples from 296 healthy individuals was scored positive by UroSEEK (specificity 99.5%, CI 97% to 297 100%). Twenty-six (6.5%) of the 395 patients in this cohort who did not develop BC had a urine sample collected 0 -5 years after surgery. We were to evaluate a total of 355 322 patients that donated urines and whose BC contained a mutation in at least one of and ranged from 0.08% to 93%. The most commonly altered genes were FGFR3 (43% 370 of the 134 mutations) and TP53 (30% of the 134 mutations; Figure 2B ). Seven percent 371 of the 135 patients who did not develop recurrent BC during the course of the study had 372 a detectable mutation in their urinary cell sample (these are considered to be false 373 positives; see Discussion). The mean interval between a positive multiplex assay test 374 and the diagnosis of recurrent BC was 7 months (range 0 to 51 months).
376
Mutations in the TERT promoter were detected in 51% of the urinary cell samples from 377 patients that developed recurrent BC during the study interval (95% CI 44% to 58%;
378 Supplementary Table 2 and Supplementary File 9). The mean TERT mutant allele 379 frequency in the urinary cells with detectable mutations was 6% and ranged from 0.23% 380 to 43%. Mutations were detected in the same three positions observed in the urinary 381 cells of the Early Detection cohort. 10% (95% CI 83% to 94%) of the 135 patients who 382 did not develop recurrent BC during the course of the study had a detectable TERT 383 promoter mutation in their urine sample (false positives). The mean interval between a 384 positive TERT test and the diagnosis of recurrent BC was 7 months (range 0 to 40 385 months).
387
Aneuploidy was detected in 30% (95% CI 24% to 37%) of the urinary cell samples from 388 the patients that developed recurrent BC during the course of the study 389 (Supplementary Table 2 and Supplementary File 10). The most commonly altered arms 390 were 8p, 8q, and 9p, as in the Early Detection cohort. Two percent of the 135 patients 391 who did not develop recurrent BC during the course of the study exhibited aneuploidy in 392 at least one of their urinary cell samples.
394
Markers in combination. As noted above, the ten-gene multiplex assay, the TERT 395 singleplex assay, and the aneuploidy assays yielded 49%, 51%, and 30% sensitivities, 396 respectively, when used separately ( Supplementary Table 2 and Supplementary Files 397 8, 9 and 10) . Thirty-two samples without TERT promoter mutations could be detected 398 by mutations in one of the other ten genes ( Figure 3B and Supplementary File 8).
399
Conversely, 41 samples without detectable mutations in the multiplex assay could be 400 detected by virtue of TERT promoter mutations. Three of the urinary cell samples 401 without any detectable mutations could be detected by the assay for aneuploidy. Thus, 402 the sensitivity of UroSEEK was 66% (95% CI 59% to 73%) Supplementary Table 2 ).
403
Fouteen percent of the 135 patients in this cohort who did not develop BC during the 404 course of the study scored positive by the UroSEEK test, yielding a specificity of 86% 405 (95% CI 77% to 91%). On average, UroSEEK positivity preceded the diagnosis of BC 406 by 7 months, and in 47 cases by more than one year ( Figure 4B and Supplementary 407 File 7).
409
There were 196 patients in the Surveillance cohort in whom cytology was available 410 ( Supplementary File 7) . Among the 120 patients who developed recurrent BC in this 411 cohort, 30 (25%) were positive by cytology. Conversely, no positive cytology results 412 were observed in patients whose tumors did not recur. UroSEEK was positive in 90% 413 of the recurrent BC patients whose urines were positive by cytology and in 61% of the 414 90 recurrent BC patients whose urines were negative by cytology. Thus in 415 combination, UroSEEK plus cytology afforded 71% sensitivity (95% CI 61.84% to 78.77)
416
( Figure 3D and Supplementary File 5). Among the 76 patients who did not develop 417 recurrent BC during the course of the study and in whom cytology was available, 18% 423 The advantage of UroSEEK over cytology was particularly evident in low-grade tumors 424 (Papillary urothelial neoplasms of low malignant potential and non-invasive low grade 425 papillary urothelial carcinomas). There were a total of 49 low-grade tumors evaluated in 426 this study in whom cytology was available (six from the Early Detection cohort and 43 427 from the Surveillance cohort). None of these low-grade tumors were detected by 428 cytology (0% sensitivity; 95% CI 0.0% to 6.7%) In contrast, UroSEEK detected 67% 429 (95% CI 51% to 81%) of the low-grade tumors (identical rate of 67% in both cohorts; Supplementary Table 3 ). Our purpose for developing UroSEEK was not to replace cytology but rather to augment 457 it. Cytology is a non-invasive test that is highly specific, and in expert hands nearly 458 always indicates the presence of a BC when positive. This specificity was verified in our 459 study: all of the 51 patients whose urine samples were positive by cytology developed 460 biopsy-proven cancer. However, cytology is not particularly sensitive. UroSEEK adds 461 considerably to sensitivity, as it raised the sensitivity of cytology from 43% to 95% in the 462 Early Detection Cohort and from 25% to 71% in the Surveillance cohort. This sensitivity 463 was highlighted by the fact that UroSEEK positive results preceded clinical diagnosis or 464 positive cytology by months to years.
Low vs. high grade urothelial neoplasms (both cohorts)

466
The advantage of using UroSEEK in addition to cytology was particularly evident for 467 low-grade tumors. Cytology was negative in all 49 patients with such tumors, while 2/3 468 were positive with UroSEEK. Another example of the utility of the combination of 469 UroSEEK plus cytology was evident in patients who had an equivocal cytology reading.
470
A relatively large number of urine samples receive such an equivocal cytologic reading, 471 even in the hands of a sub-specialized, board-certified cytopathology expert such as 472 employed in the current study [49] . In the Early Detection Cohort, for example, 105 473 urine samples were scored as "atypical", and of these cases, 19% developed 474 recurrence while the other 81% did not. UroSEEK was positive in 95% of the atypical 475 cases that developed BC, but only in 13% of the atypical cases that did not develop 476 cancer. These results demonstrate that UroSEEK can be used to more confidently 477 interpret atypical cytology results.
479
Although UroSEEK is more sensitive than cytology, it is less specific. In this study, we 480 were able to judge specificity in several independent ways. The first, and in some ways, 481 most straightforward, was in a collection of urine samples from healthy individuals. In 482 188 such individuals, we found only one instance of a positive test, yielding a specificity 483 of 99.5% (CI 97% to 100%). That high specificity can be considered the technical 484 specificity of the test, but biological specificities are also important. In the Early 485 Detection cohort, 26 of the 395 patients who did not develop BC scored positive, 486 yielding a specificity of 93% (CI 90.50% to 96%), i.e., 6.5% false positives. primary tumors harbored mutations in at least one of the 11 genes assessed through 546 the multiplex or singleplex assays. A minimum follow-up of 12 months was from date of 547 urine collection was required for cases with no evidence of incident or recurrent tumors 548 in the Early Detection or Surveillance cohorts, respectively. Urine samples were 549 collected prior to any procedures, such as cystoscopy, performed during the patients' needle. One to three cores were obtained per tumor and placed in 1.5-mL sterile tubes 573 for DNA purification, as previously described [14] . Electronic medical records were 574 reviewed to obtain medical history and follow up data in all patients.
576 577
Mutation analysis 578 Three separate assays were used to search for abnormalities in urinary cell DNA. First, 579 a multiplex PCR was used to detect mutations in regions of ten genes commonly 580 mutated in urologic malignancies CDKN2A, ERBB2, FGFR3, HRAS, KRAS, MET, MLL, 581 PIK3CA, TP53, . The 57 primer pairs used for this multiplex PCR were 582 divided in a total of three multiplex reactions, each containing non-overlapping 583 amplicons ( Supplementary Table 13 ) These primers were used to amplify DNA in 25 uL 584 reactions as previously described [42] except that 15 cycles was used for the initial 585 amplification. Second, the TERT promoter region was evaluated. A single amplification 586 primer was used to amplify a 73-bp segment containing the region of the TERT 587 promoter known to harbor mutations in BC [14] . The conditions used to amplify it were 588 the same as used in the multiplex reactions described above except that Phusion GC 589 Buffer (Thermo-Fisher) instead of HF buffer was used and 20 cycles were used for the 590 initial amplification. Note that the TERT promoter region could not be included in the 591 multiplex PCR because of the high GC content of the former. PCR products were 592 purified with AMPure XP beads (Beckman Coulter, PA, USA) and 0.25% of the purified 593 PCR products (multiplex) or 0.0125% of the PCR products (TERT singleplex) were then 594 amplified in a second round of PCR, as described in [57] . The PCR products from the 595 second round of amplification were then purified with AMPure and sequenced on an 596 Illumina instrument. For each mutation identified, the mutant allele frequency (MAF) 597 was determined by dividing the number of uniquely identified reads with mutations [42] 598 by the number of total uniquely identified reads. Each DNA sample was assessed in 599 two independent PCRs, for both the TERT promoter and multiplex assays, and samples 
